• Abhijay Jalota, Brian K Lindner, Beje Thomas, and Edgar V Lerma.
• MedStar Georgetown University Hospital, 3800 Reservoir Rd NW, Washington, DC 20007, United States. Electronic address: abhijay.jalota@gmail.com.
• Dis Mon. 2021 Feb 1; 67 (2): 101017.

AbstractHepatitis C virus (HCV) is associated with increased mortality and morbidity in patients with chronic kidney disease (CKD). The early detection and treatment of Hepatitis C associated with kidney disease is paramount to preventing the progressive loss of kidney function. HCV treatment until the advent of direct acting anti-viral agents (DAAs) was limited to interferon and ribavirin. Interferon and ribavirin treatment resulted in only modest success but with frequent adverse events and poor tolerability. Furthermore, interferon and ribavirin could not be used in certain patient populations including those with advanced CKD, were on dialysis, or those who have received a kidney transplant. DAAs have now made treatment possible in these sub-groups with a sustained viral response (SVR) of 90-100% and minimal side effects. DAAs have helped increase transplant rates by allowing for the use of HCV positive kidneys in recipients who are HCV negative. Although the choice of DAAs should be carefully considered and based on patient characteristics, concomitant medications, and HCV genotype.Copyright © 2020 Elsevier Inc. All rights reserved.

29 keywords...

hide…